Usefulness of a Nanoparticle Formulation to Investigate Some Hemodynamic Parameters of a Poorly Soluble Compound

Sigfridsson, Kalle,1964Chalmers tekniska högskola,Chalmers University of Technology (author)

Drug solubility is an important issue when progressing investigational compounds into clinical candidates. The present paper describes the development and characterization of a nanosuspension that was formulated to overcome problems with poor water solubility and possible adverse events caused by cosolvent mixtures, using ticagrelor as a model compound. A homogeneous nanosuspension of ticagrelor was formed using a wet milling approach, which yielded particle sizes around 230 nm. The nanosuspensions were chemically stable for at least 10 months at both room temperature and when refrigerated, and physically (i.e., particle size) stable for at least 10 months under refrigeration, and approximately 3 years at room temperature and when frozen. One rat model and two dog models were used to assess the pharmacokinetics and hemodynamic-related effects following intravenous administration of nanoparticles. There were no biologically consistent or dose-dependent effects of the nanoparticles on the hemodynamic parameters tested, that is, heart rate, mean aortic pressure, cardiac output, left femoral artery blood flow, or cardiac inotropy (measured as max dP/dt). In conclusion, a stable ticagrelor nanosuspension formulation was developed, suitable for intravenous administration. At the doses evaluated, this formulation was without hemodynamic effects in three sensitive preclinical models. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:2194-2202, 2011

MEDICIN OCH HÄLSOVETENSKAP Medicinska och farmaceutiska grundvetenskaper Farmaceutiska vetenskaper hsv//swe
MEDICAL AND HEALTH SCIENCES Basic Medicine Pharmaceutical Sciences hsv//eng
injectables
rats
ticagrelor
amorphous drug nanosuspensions
stability
absorption
improvement
cyclodextrins
nanoparticles
delivery
preclinical
particle-size reduction
intravenous
future
systems
pharmacokinetics

In:Journal of Pharmaceutical Sciences: Elsevier BV100:6, s. 2194-22021520-60170022-3549

By the author/editor: Sigfridsson, Kal ...; Bjorkman, J. A.; Skantze, P.; Zachrisson, H.

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Pharmaceutical S ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.